CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SIN3B (ImmuneEditome ID:23309)

1. Gene summary of enriched editing regions for SIN3B

check button Gene summary
Gene informationGene symbol

SIN3B

Gene ID

23309

GeneSynonyms-
GeneCytomap

19p13.11

GeneTypeprotein-coding
GeneDescriptionpaired amphipathic helix protein Sin3b|SIN3 homolog B, transcriptional regulator|SIN3 transcription regulator homolog B|histone deacetylase complex subunit Sin3b|transcriptional corepressor Sin3b
GeneModificationdate20230515
UniprotIDO75182;M0QYC5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:16855433-16856890:+ENST00000596802.4ENSG00000127511.8SIN3BUTR3AluJb,L1MCa,AluSz6,AluSq2,MIRchr19:16855433-16856890:+.alignment


Top

2. Tumor-specific enriched editing regions for SIN3B


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:16855433-16856890:+BRCAEER2.7686e-02image
ENSG00000127511.8,SIN3BBRCAEAG2.6921e-02image
ENSG00000127511.8,SIN3BTHCAEAG2.4890e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000127511.8,SIN3BLIHCPathEAG1.8883e-021.1542e-02-0.4704image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr19:16855433-16856890:+GBMEER4.0421e-023.0904e-024.7500e+00image
ENSG00000127511.8,SIN3BGBMEAG4.0421e-023.0904e-024.7500e+00image
chr19:16855433-16856890:+SKCMEER8.2659e-031.2696e-022.7640e-01image
ENSG00000127511.8,SIN3BSKCMEAG8.2659e-031.2696e-022.7640e-01image

Top

3. Enriched editing regions and immune related genes for SIN3B


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:16855433-16856890:+GBMEERENSG00000148841,ITPRIP0.36143.1627e-031.7354e-060.4009imageNDKC1;HNRNPA1;HNRNPLNADendritic_cells_activatedGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION
chr19:16855433-16856890:+GBMEERENSG00000136371,MTHFS0.32268.5398e-031.1030e-060.4078imageNDKC1;HNRNPA1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:16855433-16856890:+TGCTEERENSG00000164414,SLC35A10.39972.7424e-044.3500e-060.4070imageNDKC1;HNRNPA1;HNRNPLNAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
chr19:16855433-16856890:+TGCTEERENSG00000119335,SET-0.37221.0964e-038.0714e-07-0.4342imageNDKC1;HNRNPA1;HNRNPLSETT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr19:16855433-16856890:+TGCTEERENSG00000142046,TMEM910.31888.4804e-034.0061e-060.4084imageNDKC1;HNRNPA1;HNRNPLNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_G2M_CHECKPOINT

More results



Top

4. Enriched editing regions and immune related splicing for SIN3B


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:16855433-16856890:+
TGCTEERESENSG00000092841.14chr1256158683:56158711:56159586:56159622:56159974:561599870.38335.8236e-035.0681e-060.4060imageNHNRNPA1;HNRNPLNAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
ENSG00000127511.8,SIN3B
TGCTEAGA3ENSG00000075413.13chr14103467078:103467191:103468080:103468186:103468032:1034681860.33523.1801e-022.3310e-060.4190imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184MARK3NeutrophilsGSVA_HALLMARK_SPERMATOGENESIS
chr19:16855433-16856890:+
TGCTEERIRENSG00000169689.10chr1782018701:82019381:82019857:820199090.34851.2568e-021.3575e-060.4261imageNHNRNPA1NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS
chr19:16855433-16856890:+
TGCTEERA3ENSG00000144029.7chr295106422:95106457:95101676:95101723:95101676:951047300.36221.1218e-023.9144e-060.4088imageNDKC1;HNRNPA1;HNRNPLNAMacrophages_M2GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000127511.8,SIN3B
TGCTEAGMEXENSG00000198467.9chr935684250:35684315:35684487:35684520:35685268:35685339:35685433:356854660.32634.1004e-024.9987e-060.4047imageNACIN1;ADAR;AIFM1;ALYREF;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP7;LIN28;LIN28A;LSM11;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:16855433-16856890:+
TGCTEERMEXENSG00000198467.9chr935684250:35684315:35684487:35684520:35685268:35685339:35685433:356854660.32634.3299e-024.9987e-060.4047imageNDKC1;HNRNPA1;HNRNPLNAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000127511.8,SIN3B
TGCTEAGA3ENSG00000213066.7chr6167010812:167010893:167022408:167022631:167022411:1670226310.25511.0923e-026.4330e-050.4084imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG;ZNF184NA
chr19:16855433-16856890:+
TGCTEERIRENSG00000099624.3chr191244314:1244440:1244736:1244824-0.43281.3533e-031.8031e-06-0.4215imageNHNRNPA1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V1
chr19:16855433-16856890:+
TGCTEERESENSG00000083223.13chr986287958:86288744:86298766:86299272:86301275:863016010.25264.4433e-023.1333e-060.4470imageNDKC1;HNRNPA1;HNRNPLNAMast_cells_restingGSVA_HALLMARK_DNA_REPAIR
ENSG00000127511.8,SIN3B
TGCTEAGA5ENSG00000128973.7chr1568211262:68211318:68211674:68211863:68211555:68211863-0.35831.3028e-022.0986e-06-0.4207imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMacrophages_M2GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

More results



Top

5. Enriched editing regions and immune infiltration for SIN3B


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000127511.8,SIN3BACCEAGMast_cells_resting1.5774e-020.3619image
chr19:16855433-16856890:+BLCAEERT_cells_CD4_naive2.8650e-02-0.1310image
ENSG00000127511.8,SIN3BBLCAEAGT_cells_CD4_naive2.0974e-02-0.1379image
chr19:16855433-16856890:+CESCEERT_cells_CD81.4282e-030.2192image
ENSG00000127511.8,SIN3BCESCEAGT_cells_CD81.4282e-030.2192image
ENSG00000127511.8,SIN3BCOADEAGEosinophils2.2246e-02-0.2449image
ENSG00000127511.8,SIN3BDLBCEAGT_cells_gamma_delta7.8913e-030.4358image
chr19:16855433-16856890:+ESCAEEREosinophils1.0533e-020.2463image
ENSG00000127511.8,SIN3BESCAEAGEosinophils1.0403e-020.2456image
chr19:16855433-16856890:+GBMEERT_cells_CD4_memory_activated1.3890e-030.2745image
ENSG00000127511.8,SIN3BGBMEAGT_cells_CD4_memory_activated1.3890e-030.2745image
chr19:16855433-16856890:+HNSCEERMacrophages_M22.4451e-030.1562image
ENSG00000127511.8,SIN3BHNSCEAGMacrophages_M22.4451e-030.1562image
ENSG00000127511.8,SIN3BKICHEAGEosinophils5.2036e-030.4620image
chr19:16855433-16856890:+KIRPEERMonocytes2.9090e-02-0.3028image
ENSG00000127511.8,SIN3BKIRPEAGMonocytes2.9090e-02-0.3028image
chr19:16855433-16856890:+LGGEERT_cells_follicular_helper3.5864e-03-0.1685image
ENSG00000127511.8,SIN3BLGGEAGT_cells_follicular_helper3.5864e-03-0.1685image
ENSG00000127511.8,SIN3BLIHCEAGMast_cells_resting4.8316e-030.5007image
chr19:16855433-16856890:+LUSCEERB_cells_memory1.2633e-020.1551image
ENSG00000127511.8,SIN3BLUSCEAGB_cells_memory1.2633e-020.1551image
chr19:16855433-16856890:+MESOEERB_cells_naive3.3185e-02-0.4110image
ENSG00000127511.8,SIN3BMESOEAGB_cells_naive3.3185e-02-0.4110image
chr19:16855433-16856890:+OVEERMacrophages_M13.6738e-02-0.1909image
ENSG00000127511.8,SIN3BOVEAGMacrophages_M14.0995e-02-0.1869image
chr19:16855433-16856890:+PCPGEERMast_cells_resting2.9456e-020.2767image
ENSG00000127511.8,SIN3BPCPGEAGMast_cells_resting2.9456e-020.2767image
chr19:16855433-16856890:+PRADEEREosinophils2.0208e-020.1829image
ENSG00000127511.8,SIN3BPRADEAGEosinophils1.9744e-020.1830image
chr19:16855433-16856890:+READEERNeutrophils3.7993e-020.3522image
ENSG00000127511.8,SIN3BREADEAGNeutrophils3.7993e-020.3522image
chr19:16855433-16856890:+SARCEERMast_cells_resting1.7335e-020.2235image
ENSG00000127511.8,SIN3BSARCEAGMast_cells_resting1.7335e-020.2235image
chr19:16855433-16856890:+SKCMEERNK_cells_resting1.0232e-02-0.1410image
ENSG00000127511.8,SIN3BSKCMEAGNK_cells_resting1.0232e-02-0.1410image
chr19:16855433-16856890:+STADEERDendritic_cells_resting3.4833e-020.1766image
ENSG00000127511.8,SIN3BSTADEAGDendritic_cells_resting3.5351e-020.1743image
chr19:16855433-16856890:+TGCTEERMacrophages_M22.0792e-02-0.2117image
ENSG00000127511.8,SIN3BTGCTEAGMacrophages_M22.0792e-02-0.2117image
chr19:16855433-16856890:+UCECEERT_cells_CD81.0476e-020.2643image
ENSG00000127511.8,SIN3BUCECEAGT_cells_CD81.0476e-020.2643image


Top

6. Enriched editing regions and immune gene sets for SIN3B


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000127511.8,SIN3BACCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.5898e-020.3357image
ENSG00000127511.8,SIN3BBLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.4108e-020.1466image
chr19:16855433-16856890:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.8506e-020.1409image
ENSG00000127511.8,SIN3BBRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.6836e-020.1016image
chr19:16855433-16856890:+BRCAGSVA_HALLMARK_NOTCH_SIGNALINGEER1.3537e-02-0.1140image
chr19:16855433-16856890:+CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.7280e-050.2721image
ENSG00000127511.8,SIN3BCESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.7280e-050.2721image
ENSG00000127511.8,SIN3BCOADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.0882e-020.2197image
ENSG00000127511.8,SIN3BGBMGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG6.3932e-040.2923image
chr19:16855433-16856890:+GBMGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER6.3932e-040.2923image
chr19:16855433-16856890:+HNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.2913e-030.1658image
ENSG00000127511.8,SIN3BHNSCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.2913e-030.1658image
ENSG00000127511.8,SIN3BKIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG2.5076e-020.3105image
chr19:16855433-16856890:+KIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.5076e-020.3105image
ENSG00000127511.8,SIN3BLGGGSVA_HALLMARK_G2M_CHECKPOINTEAG1.4975e-02-0.1411image
chr19:16855433-16856890:+LGGGSVA_HALLMARK_G2M_CHECKPOINTEER1.4975e-02-0.1411image
ENSG00000127511.8,SIN3BLIHCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG2.5817e-030.5302image
chr19:16855433-16856890:+LUSCGSVA_HALLMARK_MYC_TARGETS_V2EER3.8064e-02-0.1292image
ENSG00000127511.8,SIN3BLUSCGSVA_HALLMARK_MYC_TARGETS_V2EAG3.8064e-02-0.1292image
chr19:16855433-16856890:+MESOGSVA_HALLMARK_MYC_TARGETS_V1EER1.6602e-02-0.4568image
ENSG00000127511.8,SIN3BMESOGSVA_HALLMARK_MYC_TARGETS_V1EAG1.6602e-02-0.4568image
chr19:16855433-16856890:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.3594e-020.1942image
ENSG00000127511.8,SIN3BOVGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG2.9717e-020.1985image
ENSG00000127511.8,SIN3BPCPGGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.0055e-02-0.2947image
chr19:16855433-16856890:+PCPGGSVA_HALLMARK_NOTCH_SIGNALINGEER2.0055e-02-0.2947image
chr19:16855433-16856890:+PRADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER3.9069e-02-0.1628image
ENSG00000127511.8,SIN3BREADGSVA_HALLMARK_ANGIOGENESISEAG3.9481e-020.3497image
chr19:16855433-16856890:+READGSVA_HALLMARK_ANGIOGENESISEER3.9481e-020.3497image
ENSG00000127511.8,SIN3BSARCGSVA_HALLMARK_G2M_CHECKPOINTEAG3.3407e-03-0.2738image
chr19:16855433-16856890:+SARCGSVA_HALLMARK_G2M_CHECKPOINTEER3.3407e-03-0.2738image
chr19:16855433-16856890:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0677e-040.1932image
ENSG00000127511.8,SIN3BSKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0677e-040.1932image
chr19:16855433-16856890:+STADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.4746e-020.2036image
ENSG00000127511.8,SIN3BSTADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG5.6592e-030.2279image
chr19:16855433-16856890:+TGCTGSVA_HALLMARK_MYC_TARGETS_V1EER2.3349e-03-0.2765image
ENSG00000127511.8,SIN3BTGCTGSVA_HALLMARK_MYC_TARGETS_V1EAG2.3349e-03-0.2765image
ENSG00000127511.8,SIN3BTHCAGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG8.0888e-04-0.2622image
ENSG00000127511.8,SIN3BTHYMGSVA_HALLMARK_MTORC1_SIGNALINGEAG9.0088e-030.3893image
ENSG00000127511.8,SIN3BUCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7474e-03-0.3071image
chr19:16855433-16856890:+UCECGSVA_HALLMARK_MITOTIC_SPINDLEEER2.7474e-03-0.3071image
ENSG00000127511.8,SIN3BUCSGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.4194e-030.4766image
ENSG00000127511.8,SIN3BUVMGSVA_HALLMARK_APICAL_JUNCTIONEAG4.4763e-040.5546image


Top

7. Enriched editing regions and drugs for SIN3B


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000127511.8,SIN3BACCBosutinibEAG5.2153e-03-0.4140image
chr19:16855433-16856890:+BLCAAxitinibEER3.6751e-040.2118image
ENSG00000127511.8,SIN3BBLCAAxitinibEAG3.5105e-040.2121image
ENSG00000127511.8,SIN3BBRCAEHT.1864EAG5.2966e-03-0.1278image
chr19:16855433-16856890:+BRCAEHT.1864EER5.5870e-03-0.1278image
chr19:16855433-16856890:+CESCBortezomibEER1.9625e-02-0.1613image
ENSG00000127511.8,SIN3BCESCBortezomibEAG1.9625e-02-0.1613image
ENSG00000127511.8,SIN3BCOADGefitinibEAG8.9052e-030.2789image
ENSG00000127511.8,SIN3BDLBCCHIR.99021EAG1.3456e-02-0.4082image
chr19:16855433-16856890:+ESCAGW843682XEER4.9657e-02-0.1903image
chr19:16855433-16856890:+GBMBI.D1870EER1.0637e-040.3297image
ENSG00000127511.8,SIN3BGBMBI.D1870EAG1.0637e-040.3297image
chr19:16855433-16856890:+HNSCGNF.2EER5.2089e-04-0.1791image
ENSG00000127511.8,SIN3BHNSCGNF.2EAG5.2089e-04-0.1791image
ENSG00000127511.8,SIN3BKICHBIRB.0796EAG4.4127e-03-0.4697image
chr19:16855433-16856890:+KIRCEpothilone.BEER3.9637e-020.2041image
ENSG00000127511.8,SIN3BKIRCEpothilone.BEAG6.6944e-030.2631image
chr19:16855433-16856890:+KIRPCHIR.99021EER2.0197e-02-0.3244image
ENSG00000127511.8,SIN3BKIRPCHIR.99021EAG2.0197e-02-0.3244image
ENSG00000127511.8,SIN3BLGGBIBW2992EAG2.3140e-03-0.1761image
chr19:16855433-16856890:+LGGBIBW2992EER2.3140e-03-0.1761image
ENSG00000127511.8,SIN3BLIHCDasatinibEAG7.1533e-03-0.5055image
ENSG00000127511.8,SIN3BMESOFH535EAG1.0246e-020.4856image
chr19:16855433-16856890:+MESOFH535EER1.0246e-020.4856image
ENSG00000127511.8,SIN3BPAADBMS.536924EAG2.9998e-02-0.3479image
ENSG00000127511.8,SIN3BPCPGAMG.706EAG5.0163e-03-0.3520image
chr19:16855433-16856890:+PCPGAMG.706EER5.0163e-03-0.3520image
chr19:16855433-16856890:+SARCCMKEER7.4563e-040.3127image
ENSG00000127511.8,SIN3BSARCCMKEAG7.4563e-040.3127image
ENSG00000127511.8,SIN3BSKCMGW843682XEAG4.6048e-040.1915image
chr19:16855433-16856890:+SKCMGW843682XEER4.6048e-040.1915image
ENSG00000127511.8,SIN3BSTADCyclopamineEAG1.2044e-020.2080image
chr19:16855433-16856890:+TGCTEpothilone.BEER5.1343e-040.3137image
ENSG00000127511.8,SIN3BTGCTEpothilone.BEAG5.1343e-040.3137image
ENSG00000127511.8,SIN3BTHCABMS.708163EAG1.7799e-030.2452image
ENSG00000127511.8,SIN3BTHYMCCT018159EAG1.0051e-020.3841image
chr19:16855433-16856890:+UCECImatinibEER5.6497e-030.2848image
ENSG00000127511.8,SIN3BUCECImatinibEAG5.6497e-030.2848image
ENSG00000127511.8,SIN3BUCSBortezomibEAG1.5104e-03-0.4742image
ENSG00000127511.8,SIN3BUVMMetforminEAG7.2796e-04-0.5373image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType